Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Lawrence

Vascular Surgery Cedar Rapids, IA Medical Doctor

NPI 1083698088 CMS profile 48975

202 10Th Street Se, Cedar Rapids, IA 52403

Open in the dashboard

General payments

$14,895

125 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Lawrence of Cedar Rapids, IA is reported in the CMS Open Payments database as having received $14,895 across 125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,715 19
2024 General $1,132 17
2023 General $618 11
2022 General $736 16
2021 General $4,027 31
2020 General $130 3
2019 General $6,538 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Lawrence
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to David Lawrence were reported at $1,715. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year David Lawrence Vascular Surgery median Middle half National median
2019 $6,538 $796 $226–$2,363 $163
2020 $130 $348 $118–$1,110 $114
2021 $4,027 $471 $158–$1,421 $132
2022 $736 $725 $222–$2,183 $149
2023 $618 $836 $257–$2,440 $160
2024 $1,132 $909 $252–$2,619 $164
2025 $1,715 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $6,239 20 payments
  2. Medtronic, Inc. $4,397 31 payments
  3. Bolton Medical Inc $1,318 8 payments
  4. W. L. Gore & Associates, Inc. $509 4 payments
  5. Silk Road Medical, Inc. $419 5 payments
  6. LeMaitre Vascular, Inc. $305 6 payments
  7. Abbott Laboratories $303 7 payments
  8. AngioDynamics, Inc. $215 8 payments
  9. Janssen Pharmaceuticals, Inc $176 7 payments
  10. Terumo Medical Corporation $149 1 payment
  11. Other $866 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $7,063 9 payments
  2. Food and Beverage $5,382 115 payments
  3. Consulting Fee $2,450 1 payment
Products named General payments · program years 2019–2025
  1. IN.PACT Admiral $6,227 17 payments
  2. TurboHawk $2,488 3 payments
  3. HawkOne $761 9 payments
  4. TREO ABDOMINAL STENT-GRAFT SYSTEM $579 4 payments
  5. ENROUTE Transcarotid Stent $324 4 payments
  6. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $324 4 payments
  7. CONCERTOTM $299 4 payments
  8. EXCLUDER Conformable AAA Endoprosthesis with Active Control $291 2 payments
  9. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $268 2 payments
  10. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $268 2 payments
  11. Other $3,746 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

132

Median for Vascular Surgery: 122

Drug cost

$19,791

Median for Vascular Surgery: $14,135

Branded share of claims

78.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 31 $19,142
Clopidogrel Clopidogrel Bisulfate Brand 73 $536
Cilostazol Generic 16 $89
Simvastatin Generic 12 $24

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 99 billing codes

Paid by Medicare

$275,894

Of which drugs: $519

Medicare patients

542

Average age 76

Services billed

6,515

244 women, 298 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 50%
Chronic kidney disease 43%
Diabetes 40%
Heart failure 28%
COPD 27%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 41 5,150 $519

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record